Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Grebely

Showing results (361-370 of 368) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 368 results.
Journal of Behavioral Addictions|May 20, 2025
A clarion call to the addiction science community: It's time to resist the anti-scientific policies of the US Trump administrationThomas F Babor, Bryon Adinoff, Luke Clark, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The American Journal of Drug and Alcohol Abuse|November 7, 2025
A clarion call to the addiction science community: it's time to resist the anti-scientific policies of the US Trump administrationThomas F Babor, Bryon Adinoff, Luke Clark, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
The Lancet. Gastroenterology & Hepatology|February 17, 2024
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission updateGraham S Cooke, Barnaby Flower, Evan Cunningham, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
Nature Medicine|June 5, 2025
The People-First Liver CharterJeffrey V Lazarus, Dana Ivancovsky Wajcman, Silvana Pannain, et al.
Pageof 37

Showing results (361-370 of 368) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 368 results.
Journal of Behavioral Addictions|May 20, 2025
A clarion call to the addiction science community: It's time to resist the anti-scientific policies of the US Trump administrationThomas F Babor, Bryon Adinoff, Luke Clark, et al.
The International Journal on Drug Policy|November 2, 2018
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapyJason Grebely, Brian Conway, Evan B Cunningham, et al.
The American Journal of Drug and Alcohol Abuse|November 7, 2025
A clarion call to the addiction science community: it's time to resist the anti-scientific policies of the US Trump administrationThomas F Babor, Bryon Adinoff, Luke Clark, et al.
The International Journal on Drug Policy|October 24, 2018
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY studyEvan B Cunningham, Janaki Amin, Jordan J Feld, et al.
The Lancet. Gastroenterology & Hepatology|January 10, 2018
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trialJason Grebely, Olav Dalgard, Brian Conway, et al.
The Lancet. Gastroenterology & Hepatology|February 17, 2024
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission updateGraham S Cooke, Barnaby Flower, Evan Cunningham, et al.
The Lancet. Gastroenterology & Hepatology|October 8, 2017
Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in EuropeAlison D Marshall, Evan B Cunningham, Stine Nielsen, et al.
Nature Medicine|June 5, 2025
The People-First Liver CharterJeffrey V Lazarus, Dana Ivancovsky Wajcman, Silvana Pannain, et al.
Pageof 37